IRIS Accounts Production v23.3.0.418 11584266 Board of Directors Board of Directors 1.10.22 30.9.23 30.9.23 false true false false false true false Ordinary 0.010 A Ordinary 0.10000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh115842662022-09-30115842662023-09-30115842662022-10-012023-09-30115842662021-09-30115842662021-10-012022-09-30115842662022-09-3011584266ns10:Originalns15:EnglandWales2022-10-012023-09-3011584266ns14:PoundSterlingns10:Original2022-10-012023-09-3011584266ns10:Originalns10:Director12022-10-012023-09-3011584266ns10:Original2022-10-012023-09-3011584266ns10:Originalns10:Director22022-10-012023-09-3011584266ns10:Original2023-09-3011584266ns10:Originalns10:PrivateLimitedCompanyLtd2022-10-012023-09-3011584266ns10:Originalns10:SmallEntities2022-10-012023-09-3011584266ns10:Originalns10:AuditExempt-NoAccountantsReport2022-10-012023-09-3011584266ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-10-012023-09-3011584266ns10:SmallCompaniesRegimeForAccountsns10:Original2022-10-012023-09-3011584266ns10:Originalns10:FullAccounts2022-10-012023-09-3011584266ns10:Original12022-10-012023-09-3011584266ns10:Originalns10:OrdinaryShareClass12022-10-012023-09-3011584266ns10:Originalns10:OrdinaryShareClass22022-10-012023-09-3011584266ns10:Originalns10:Director32022-10-012023-09-3011584266ns10:Originalns10:Director52022-10-012023-09-3011584266ns10:Originalns10:Director62022-10-012023-09-3011584266ns10:Originalns10:Director72022-10-012023-09-3011584266ns10:Originalns10:RegisteredOffice2022-10-012023-09-3011584266ns10:Original2022-09-3011584266ns10:Originalns5:CurrentFinancialInstruments2023-09-3011584266ns10:Originalns5:CurrentFinancialInstruments2022-09-3011584266ns10:Originalns5:Non-currentFinancialInstruments2023-09-3011584266ns10:Originalns5:Non-currentFinancialInstruments2022-09-3011584266ns5:ShareCapitalns10:Original2023-09-3011584266ns5:ShareCapitalns10:Original2022-09-3011584266ns10:Originalns5:SharePremium2023-09-3011584266ns10:Originalns5:SharePremium2022-09-3011584266ns10:Originalns5:FurtherSpecificReserve1ComponentTotalEquity2023-09-3011584266ns10:Originalns5:FurtherSpecificReserve1ComponentTotalEquity2022-09-3011584266ns10:Originalns5:FurtherSpecificReserve2ComponentTotalEquity2023-09-3011584266ns10:Originalns5:FurtherSpecificReserve2ComponentTotalEquity2022-09-3011584266ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-09-3011584266ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-09-3011584266ns5:IntangibleAssetsOtherThanGoodwillns10:Original2022-10-012023-09-3011584266ns10:Originalns5:DevelopmentCostsCapitalisedDevelopmentExpenditure2022-10-012023-09-3011584266ns10:Originalns5:PlantMachinery2022-10-012023-09-3011584266ns10:Original2021-10-012022-09-3011584266ns5:IntangibleAssetsOtherThanGoodwillns10:Original2022-09-3011584266ns5:IntangibleAssetsOtherThanGoodwillns10:Original2023-09-3011584266ns5:IntangibleAssetsOtherThanGoodwillns10:Original2022-09-3011584266ns10:Originalns5:PlantMachinery2022-09-3011584266ns10:Originalns5:PlantMachinery2023-09-3011584266ns10:Originalns5:PlantMachinery2022-09-3011584266ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-09-3011584266ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-09-3011584266ns10:Originalns5:CurrentFinancialInstruments2022-10-012023-09-3011584266ns10:Originalns10:OrdinaryShareClass12023-09-3011584266ns10:Originalns10:OrdinaryShareClass22023-09-3011584266ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-09-3011584266ns10:Originalns5:SharePremium2022-09-3011584266ns10:Originalns5:FurtherSpecificReserve1ComponentTotalEquity2022-09-3011584266ns10:Originalns5:FurtherSpecificReserve2ComponentTotalEquity2022-09-3011584266ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-10-012023-09-30
REGISTERED NUMBER: 11584266 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 September 2023

for

Ampersand Health Limited

Ampersand Health Limited (Registered number: 11584266)






Contents of the Financial Statements
for the Year Ended 30 September 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Ampersand Health Limited

Company Information
for the Year Ended 30 September 2023







DIRECTORS: N Alaghband
G C Parkes
J S Synett
M C Jamieson
I J Tobin
S M Westcott





REGISTERED OFFICE: 4 Lonsdale Road
London
NW6 6RD





REGISTERED NUMBER: 11584266 (England and Wales)





ACCOUNTANTS: Shaw Accounting Services Limited
14 Amherst Avenue
London
W13 8NQ

Ampersand Health Limited (Registered number: 11584266)

Balance Sheet
30 September 2023

30.9.23 30.9.22
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 1,449,136 1,516,007
Tangible assets 5 4,345 8,437
1,453,481 1,524,444

CURRENT ASSETS
Debtors 6 86,784 104,822
Cash at bank and in hand 46,164 16,388
132,948 121,210
CREDITORS
Amounts falling due within one year 7 287,934 482,830
NET CURRENT LIABILITIES (154,986 ) (361,620 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,298,495

1,162,824

CREDITORS
Amounts falling due after more than one
year

8

15,955

-
NET ASSETS 1,282,540 1,162,824

CAPITAL AND RESERVES
Called up share capital 9 8 7
Share premium 10 4,718,052 3,052,789
Option monies received 10 42,250 42,250
Convertible loans 10 - 825,000
Retained earnings 10 (3,477,770 ) (2,757,222 )
SHAREHOLDERS' FUNDS 1,282,540 1,162,824

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Ampersand Health Limited (Registered number: 11584266)

Balance Sheet - continued
30 September 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 October 2023 and were signed on its behalf by:




N Alaghband - Director



S M Westcott - Director


Ampersand Health Limited (Registered number: 11584266)

Notes to the Financial Statements
for the Year Ended 30 September 2023

1. STATUTORY INFORMATION

Ampersand Health Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Development costs are being amortised evenly over their estimated useful life of five years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Ampersand Health Limited (Registered number: 11584266)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2023

2. ACCOUNTING POLICIES - continued

Going concern
The Company is reliant upon further funding which is expected to be provided at a date after the financial statements are approved. However, if for any reason such funding is not forthcoming on a timetable which will enable the Company to meet its cash requirements and liabilities, further steps will need to be taken by the Company including potentially insolvency.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 11 (2022 - 13 ) .

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 October 2022 2,508,375
Additions 490,807
At 30 September 2023 2,999,182
AMORTISATION
At 1 October 2022 992,368
Charge for year 557,678
At 30 September 2023 1,550,046
NET BOOK VALUE
At 30 September 2023 1,449,136
At 30 September 2022 1,516,007

The directors consider that the Intellectual Property, currently stated in the balance sheet at net book value, is undervalued.

Ampersand Health Limited (Registered number: 11584266)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2023

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 October 2022 17,623
Additions 977
At 30 September 2023 18,600
DEPRECIATION
At 1 October 2022 9,186
Charge for year 5,069
At 30 September 2023 14,255
NET BOOK VALUE
At 30 September 2023 4,345
At 30 September 2022 8,437

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.9.23 30.9.22
£    £   
Trade debtors 77,631 88,304
Other debtors 9,153 16,518
86,784 104,822

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.9.23 30.9.22
£    £   
Trade creditors 203,788 248,967
Taxation and social security 47,803 47,929
Other creditors 36,343 185,934
287,934 482,830



8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
30.9.23 30.9.22
£    £   
Other creditors 15,955 -

Ampersand Health Limited (Registered number: 11584266)

Notes to the Financial Statements - continued
for the Year Ended 30 September 2023

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.9.23 30.9.22
value: £    £   
26,850 Ordinary £0.0001p 3 2
500 A Ordinary £0.1000p 5 5
8 7

5,725 Ordinary shares of £0.0001 were issued in the year under review at various prices giving rise to a share premium of £1,665,263 net of costs. In the year to 30 September 2022. 1,531 Ordinary shares of £0.0001 were issued in the year under review at various prices giving rise to a share premium of £689,232.

10. RESERVES
Option
Retained Share monies Convertible
earnings premium received loans Totals
£    £    £    £    £   

At 1 October 2022 (2,757,222 ) 3,052,789 42,250 825,000 1,162,817
Deficit for the year (720,548 ) (720,548 )
Cash share issue - 840,263 - - 840,263
Conversion of loan - 825,000 - (825,000 ) -
At 30 September 2023 (3,477,770 ) 4,718,052 42,250 - 1,282,532

The convertible loans which were not secured were converted into ordinary shares in the year ended 30 September 2023.

11. RELATED PARTY DISCLOSURES

During the year under review the company did not make any related party sales (2022 £12,760) .